NCT07396714Not yet recruitingEarly phase 1
the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.
Evaluation of the Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling as Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Randomized Controlled Clinical Trial.
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts. topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue. Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Feb 2027
- Lead sponsor
- Assiut University
- NCT number
- NCT07396714
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 88
- From 1 Feb 2026 to the primary completion date, 1 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Genital warts.
- Pregnancy and lactation.
- History of any bleeding, clotting disorder or using anticoagulants
- Chronic systemic diseases such as chronic renal failure, hepaticinsufficiency, and cardiovascular disorders.
- patients who received any treatment for warts in the last month before the study.
- Patients with history of neuropathy or peripheral ischemia.
- Patients with signs of inflammation or infection.
- Patients with history of a serious systemic or anaphylactic reaction or allergy to ivermectin.
Who the study is looking for
- patients with cutaneous non genital warts aged 11:80 y.
- No concurrent systemic or topical treatment of warts
Age in the registry: 11 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.